Resolved hepatitis B virus infection: an unresolved issue of terminology

WOS: 000446527500019PubMed ID: 30252716

Does resolved HBV or anti-HBc-only carry the same risk of HBV reactivation?

WOS: 000441723400010PubMed ID: 29925293

On hepatitis B virus and vasculitis

WOS: 000438624900030PubMed ID: 29948001

Quinolone resistance of gram negative bacteria from the patients with malignancies and relationship with prophylaxis

Fluoroquinolones are the most commonly used antibiotics for the treatment and prophylaxis of patients with malignancies. But resistance development is a big problem.With the aim of identifying the epidemiological data about the local fluoroquinolone resistance of the patients with malignancies followed up in the hospital or on outpatient basis, fluoroquinolone resistance of gram negative bacteria isolated from different materials of these patients was investigated. In our hospital, from January 2013 to August 2014, gram negative isolates that were isolated from the samples of patients with malignancies followed-up by Hematology and Oncology Departments were retrospectively analyzed. Within a period of one and a half years, 227 Gram negative bacteria were isolated from the materials of the patients hospitalized in our hospital. Quinolone resistance rates were 63% for E.coli, 49% for Klebsiella pneumoniae, 34% for Pseudomonas aeruginosa, 72% for Acinetobacter baumannii , with a mean of 52% for all Gram negatives. When patients who received and who did not receive quinolone prophylaxis were compared, resistance rate was 57% (26/61) for those receiving prophylaxis and 50 %( 83/166) for those who did not. In conclusion, fluoroquinolone resistance rates were considerably high and it was higher in the patients who received quinolone prophylaxis, but it wasn't statistically significant. In the oral treatment of febrile neutropenic patients, empirical treatment aims at Gram negative pathogens and considers quinolon es as the first choice; however this data raises a suspicion about the efficacy and adequacy of quinolonesFluoroquinolones are the most commonly used antibiotics for the treatment and prophylaxis of patients with malignancies. But resistance development is a big problem.With the aim of identifying the epidemiological data about the local fluoroquinolone resistance of the patients with malignancies followed up in the hospital or on outpatient basis, fluoroquinolone resistance of gram negative bacteria isolated from different materials of these patients was investigated. In our hospital, from January 2013 to August 2014, gram negative isolates that were isolated from the samples of patients with malignancies followed-up by Hematology and Oncology Departments were retrospectively analyzed. Within a period of one and a half years, 227 Gram negative bacteria were isolated from the materials of the patients hospitalized in our hospital. Quinolone resistance rates were 63% for E.coli, 49% for Klebsiella pneumoniae, 34% for Pseudomonas aeruginosa, 72% for Acinetobacter baumannii , with a mean of 52% for all Gram negatives. When patients who received and who did not receive quinolone prophylaxis were compared, resistance rate was 57% (26/61) for those receiving prophylaxis and 50 %( 83/166) for those who did not. In conclusion, fluoroquinolone resistance rates were considerably high and it was higher in the patients who received quinolone prophylaxis, but it wasn't statistically significant. In the oral treatment of febrile neutropenic patients, empirical treatment aims at Gram negative pathogens and considers quinolon es as the first choice; however this data raises a suspicion about the efficacy and adequacy of quinolone

Quinolone resistance of gram negative bacteria from the patients with malignancies and relationship with prophylaxis

Fluoroquinolones are the most commonly used antibiotics for the treatment and prophylaxis of patients with malignancies. But resistance development is a big problem.With the aim of identifying the epidemiological data about the local fluoroquinolone resistance of the patients with malignancies followed up in the hospital or on outpatient basis, fluoroquinolone resistance of gram negative bacteria isolated from different materials of these patients was investigated. In our hospital, from January 2013 to August 2014, gram negative isolates that were isolated from the samples of patients with malignancies followed-up by Hematology and Oncology Departments were retrospectively analyzed. Within a period of one and a half years, 227 Gram negative bacteria were isolated from the materials of the patients hospitalized in our hospital. Quinolone resistance rates were 63% for E.coli, 49% for Klebsiella pneumoniae, 34% for Pseudomonas aeruginosa, 72% for Acinetobacter baumannii , with a mean of 52% for all Gram negatives. When patients who received and who did not receive quinolone prophylaxis were compared, resistance rate was 57% (26/61) for those receiving prophylaxis and 50 %( 83/166) for those who did not. In conclusion, fluoroquinolone resistance rates were considerably high and it was higher in the patients who received quinolone prophylaxis, but it wasn't statistically significant. In the oral treatment of febrile neutropenic patients, empirical treatment aims at Gram negative pathogens and considers quinolones as the first choice; however this data raises a suspicion about the efficacy and adequacy of quinolones. [Med-Science 2016; 5(3.000): 805-8

Catheter-Related Bloodstream Infections: A Multicentric Five-Year Analysis

WOS: 000481718600003Objective: the aim of this study was to evaluate the catheter-related bloodstream infections (CR-BSI) devoloping in hematology and oncology departments, and intensive care units of three different hospitals from a clinical and microbiological point of view. Methods: We retrospectively evaluated the CR-BSI in hematology and oncology departments and intensive care units, and by using laboratory- and clinic-based active surveillance systems between January 2013 and December 2017 based on the definition criteria for US Centers for Disease Control and Prevention. the demographic characteristics of the patients, clinical information, catheter-related information such as the unit which the catheter was inserted, erythema in the catheter insertion site, and results of blood cultures were recorded. Isolated agents were identified by MicroScan autoSCAN-4 (Beckman Coulter, Brea, CA, USA) automatized system in addition to conventional methods. Statistical analyses were performed using MedCalc Statistical Software Version 12.7.7 (MedCalc Software bvba, Ostend, Belgium). Results: CR-BSI was detected in 46 (45% female) patients. the mean age was 61 +/- 19. 24 (52.2%) patients had permanent catheterization (port) and 22 (47.8%) had central venous catheter. Blood culture was obtained in 40 (87%) patients and there was >2 hours of interval in 24 patients. 9 (20%) had erythema at the catheter insertion site. 3 (6.5%) patients died of the infection. Duration of the treatment was 13 +/- 4 days. Gram-negatives, Gram-positives, and fungi were detected in 50%, 25.4% and 23.9% of isolates, respectively. Within 10 days after catheter and port implantation, Gram-negatives and fungi were grown, and it was statistically significant that there was no Gram-positive growth during this period. Conclusions: Analysis of surveillance data, distribution of isolated microorganisms, knowledge of antibiotic sensitivities and prediction of risk factors are important for prevention and rapid and successful treatment of CR-BSI